Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti...

Full description

Bibliographic Details
Main Authors:	Kei Muro, Taylor Salinardi, Arvind Rup Singh, Teresa Macarulla
Format:	Article
Language:	English
Published:	MDPI AG 2020-03-01
Series:	Cancers
Subjects:	colorectal cancer mCRC VEGF inhibitor anti-angiogenic therapy aflibercept clinical practice
Online Access:	https://www.mdpi.com/2072-6694/12/4/844

Similar Items

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
by: Ralf-Dieter Hofheinz, et al.
Published: (2022-07-01)

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
by: Alessandro Parisi, et al.
Published: (2020-05-01)

Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices
by: L. V. Bolotina, et al.
Published: (2018-11-01)

Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review
by: Jan Gerard Maring, et al.
Published: (2023-02-01)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
by: Francesca Pirini, et al.
Published: (2020-05-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer—A Swiss Perspective in the Context of an International Viewpoint
by: Alexander R. Siebenhüner, et al.
Published: (2022-08-01)

Clinicopathological Profiles Associated with Discordant <i>RAS</i> Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
by: Elena Brozos-Vázquez, et al.
Published: (2023-07-01)

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
by: Julia de Lima Farah, et al.
Published: (2018-10-01)

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
by: Ting-Yu Chiang, et al.
Published: (2023-03-01)

Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital
by: Meiqin Yuan, et al.
Published: (2021-05-01)

Aflibercept as a second-line therapy in metastatic colorectal cancer: A limited Indian experience
by: Govind Babu, et al.
Published: (2016-01-01)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
by: Matteo Conti, et al.
Published: (2023-07-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
by: Vasumathy Vedantham
Published: (2019-01-01)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
by: Xia-Hong You, et al.
Published: (2019-08-01)

Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer
by: Hugo Levillain, et al.
Published: (2020-12-01)

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
by: Gemma Bruera, et al.
Published: (2020-08-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
by: María San-Román-Gil, et al.
Published: (2023-01-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
by: Joseph Tintelnot, et al.
Published: (2022-12-01)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
by: Brigida Anna Maiorano, et al.
Published: (2022-10-01)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01)

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib
by: Andrea Abbona, et al.
Published: (2023-02-01)

Treatment of corneal neovascularization with topical aflibercept in a case of exposure keratopathy following cerebellar astrocytoma surgery
by: Sibel Aksoy
Published: (2019-01-01)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
by: Miaomiao Gou, et al.
Published: (2022-07-01)

Racial disparities in metastatic colorectal cancer outcomes revealed by tumor microbiome and transcriptome analysis with bevacizumab treatment
by: Lei Feng, et al.
Published: (2024-01-01)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01)

Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients
by: Thomas Helmberger, et al.
Published: (2022-10-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

Efficacy and safety of fruquintinib dose‐escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single‐arm, multicenter, phase II study
by: Sirui Tan, et al.
Published: (2023-12-01)

EFFICIENCY OF AFLIBERCEPT IN CLINICAL PRACTICE
by: A. V. Kulagina
Published: (2017-09-01)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
by: Daniele Lavacchi, et al.
Published: (2021-07-01)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
by: Lucia Scarabel, et al.
Published: (2022-11-01)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
by: Yuankai Shi, et al.
Published: (2019-05-01)

Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
by: Aditya Bansal, et al.
Published: (2017-01-01)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021-05-01)